WO2019030629A1 - Composition pour administration orale dans le traitement thérapeutique ou préventif de troubles ou de la maladie du reflux gastro-oesophagien - Google Patents

Composition pour administration orale dans le traitement thérapeutique ou préventif de troubles ou de la maladie du reflux gastro-oesophagien Download PDF

Info

Publication number
WO2019030629A1
WO2019030629A1 PCT/IB2018/055854 IB2018055854W WO2019030629A1 WO 2019030629 A1 WO2019030629 A1 WO 2019030629A1 IB 2018055854 W IB2018055854 W IB 2018055854W WO 2019030629 A1 WO2019030629 A1 WO 2019030629A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
poloxamer
comprised
gastroesophageal reflux
weight
Prior art date
Application number
PCT/IB2018/055854
Other languages
English (en)
Inventor
Umberto DI MAIO
Original Assignee
Neilos S.r.l.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neilos S.r.l. filed Critical Neilos S.r.l.
Priority to EP18762148.7A priority Critical patent/EP3664852A1/fr
Publication of WO2019030629A1 publication Critical patent/WO2019030629A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Definitions

  • the present invention relates to a composition for use in a method for treating gastroesophageal reflux disorders or disease, preferably in a method for the symptomatic treatment of gastroesophageal reflux disorders or disease, wherein said composition is for oral use, in any form of administration pharmaceutically acceptable, and comprises a mixture comprising or, alternatively, consisting of an extract of Trigonella foenum graecum and a block copolymer of ethylene oxide and propylene oxide.
  • gastroesophageal reflux is meant "the involuntary and unconscious passage of part of the gastric contents into the esophagus, without the joint participation of the gastric and abdominal muscles.”
  • the esophagus is a channel, 25-30 cm long, connecting the mouth with the stomach.
  • two sphincter structures the first between the hypopharynx and the cervical tract of the esophagus (Upper Esophageal Sphincter, UES), the second at the level of the gastroesophageal junction (Lower Esophageal Sphincter, LES).
  • the latter is a high pressure zone that represents the main anti-reflux structure, thanks to its location between the negative-pressure intrathoracic zone and the positive-pressure intra-abdominal zone. Therefore, under normal conditions, an increase in abdominal pressure has repercussions at the level of the LES, preventing the return of ingested material into the esophagus. Under physiological conditions the LES is closed and relaxes for a time of about 3-10 seconds following deglutition.
  • Other anatomical structures, in addition to the LES, which contribute to maintaining the anti-reflux barrier are:
  • the angle of His an acute angle formed between the esophagus and the gastric fundus
  • the diaphragmatic collar consisting of fasciae of the diaphragm, which wrap around the esophagus like a scarf and constrict the lumen during inspiration.
  • GSD gastroesophageal reflux disease
  • anatomical anomalies pyloric stenosis (the terminal region of the stomach, which regulates the passage of the gastric content into the duodenum);
  • functional alterations motoric alteration of the fundus (the region responsible for draining fluids).
  • Insufficiency of the esophageal clearing mechanism which has the purpose of minimising contact between the esophageal mucosa and gastric juices by acting both through esophageal peristalsis and the neutralisation of acidic residues thanks to saliva.
  • GERD GERD
  • esophageal hiatus extension of a portion of the stomach into the thorax through an opening in the diaphragm called the esophageal hiatus
  • GERD gastroduodenal contents
  • the walls of the esophageal hiatus adhere closely to the esophagus, but it can happen that the anchorage structures of the lower portion of the esophagus lose tone, favouring the ascent of a small part of the stomach into the thorax.
  • the frequent and repeated contact of regurgitated gastric materials with the esophageal mucosa exerts a harmful action on the latter, which is all the more serious the longer the contact time and the lower the pH of the reflux.
  • the persistent phlogistic action affecting the esophageal mucosa leads to an inflammatory reaction that can evolve into ulcerations, stenosis and so- called columnar metaplasia (or Barrett's epithelium, the single most important risk factor for the development of esophageal adenocarcinoma).
  • Symptoms considered to be typical are retrosternal pyrosis (defined by the patient as a burning sensation that starts at the stomach or the lower portion of the thorax and rises toward the neck) and regurgitation (perception of acidic and bitter tasting liquid inside the oral cavity).
  • GERD is one of the pathological conditions most frequently encountered by gastroenterologists.
  • GERD GERD
  • PPI proton pump inhibitors
  • Antacids are over the counter drugs and offer rapid relief of the symptoms of the pathology, but have no curative effect in cases of erosive esophagitis.
  • These drugs contain carbonates or bicarbonates which reduce the acidity in the stomach by reacting with the hydrochloric acid and releasing carbon dioxide, hb-antagonists like ranitidine, famotidine and cimetidine provide temporary relief of the symptoms, although they are slower acting than antacids. Long term use of these drugs is not recommended, since the subject may develop tolerance to them over 1-2 weeks, and in any case they have no curative effect.
  • Proton pump inhibitors are the standard drugs used in the treatment of gastroesophageal reflux pathologies. Indeed, the number of prescriptions for these drugs has doubled over the last 10 years. These drugs are often associated with prescriptions for steroidal and nonsteroidal anti-inflammatory drugs.
  • the mechanism of action of the PPIs includes blocking of the proton pump in the parietal cells of the stomach; this hydrogen/potassium ATPase pump controls the release of hydrochloric acid into the lumen of the stomach. Compared with the H2 antagonists, these drugs are faster acting and, above all, exercise a curative action of the esophageal lesions.
  • GSD gastroesophageal reflux disorder
  • the PPIs also have side effects, especially when used in combination with steroidal drugs.
  • the most commonly recorded side effects of treatment with PPIs are nausea, diarrhea, headache, insomnia and anaphylactic reactions.
  • Prokinetic agents such as cisapride and metoclopramide, activate the serotonin or dopamine receptors which increase esophageal or gastric peristalsis.
  • These drugs have a slow onset of action, a short duration and are not curative of the pathology. They also have various side effects, including tremor, dyskinesia, fatigue and an increase in adverse cardiac events, so that they are not commonly used in treating GERD.
  • alginates are also used in the symptomatic treatment of GERD.
  • Alginates such as sodium alginate, are natural polysaccharides which precipitate in contact with the gastric environment, forming a low-density gel in just a few minutes.
  • the reaction of carbonates and bicarbonates with the gastric hydrochloric acid releases carbon dioxide which is trapped in the alginate gel, forming a foam or gel (the "raft") which floats on top of the contents of the stomach.
  • the alginate gel forms in the portion of stomach near the gastroesophageal junction, precisely where the acid pocket develops. In this manner, the reflux of acid from stomach to the esophageal canal is blocked or greatly reduced.
  • alginate-based drugs also fail to resolve the causes of gastroesophageal reflux.
  • patent WO2007/133082 A1 describes a composition comprising specific polysaccharides for use in the treatment of GERD. This document does not describe the presence in the composition of a block copolymer of ethylene oxide and propylene oxide (or poloxamer).
  • Patent PL218041 B1 describes a composition comprising poloxamer 407 and methylcellulose for use in the treatment of GERD.
  • compositions or drugs for the treatment of gastroesophageal reflux that are well tolerated, effective and, if possible, free of side effects, especially in the case of individuals who have to take anti-reflux drugs or compositions for extended periods of time.
  • One object of the present invention is to provide a composition which overcomes the disadvantages listed above of the known compositions for use in a method for treating GERD.
  • the present invention provides a composition for use according to the appended claims.
  • the present invention relates to a composition (in short the composition of the invention) comprising or, alternatively, consisting of an effective amount of a mixture comprising at least or consisting of:
  • composition according of the invention comprising an effective amount of a mixture consisting of:
  • composition according to the present invention comprising an effective amount of a mixture consisting of:
  • a poloxamer type block copolymer of ethylene oxide and propylene oxide for instance poloxamer 407 and/or poloxamer 188, without the use of methylcellulose or derivatives thereof.
  • This invention further relates to a composition as defined above (the composition of the invention) for use in the therapeutic and/or preventive treatment of gastroesophageal reflux disorders or disease, and pathologies or disorders connected thereto, wherein said treatment comprises the oral administration of said composition to a subject.
  • the inventors have perfected a composition comprising an extract of Trigonella foenum graecum and a block copolymer (poloxamer) advantageous for use in the therapeutic or preventive treatment of gastroesophageal disorders and the pathologies and disorders associated with it.
  • a block copolymer polyxamer
  • the use of the poloxamer increases the effectiveness of the composition without, however, increasing the viscosity of the gel to be administered to the patient.
  • This is made possible by the temperature-dependent gelification of the poloxamer, which at room temperature has the form of a sol and creates low viscosity suspensions, but gelifies at body temperature, thus protecting the gastric and esophageal mucosa against the action of the acid.
  • method of treatment of a pathology or disorder is meant a therapy intended to restore the conditions of health of a subject, maintain existing conditions or prevent the worsening of said conditions of health.
  • prevention of a pathology or disorder is meant a therapy intended to prevent the occurrence of such a pathology or disorder in a subject, also, but only, as a complication or effect of a pre-existing pathology or disorder.
  • percentages and quantities of a component in a mixture refer to the weight of said component relative to the total weight of the mixture.
  • composition/s is meant a pharmaceutical composition, a composition for a food supplement, a composition for a food product or a composition for a medical device.
  • Fenugreek Trigonella foenum-graecum
  • the plant belongs to the family of the Fabaceae and has various names depending on the language: Fenugrec (France), Methi (Hindi), Bockshornklee (Germany), Fieno Inco (Italy), Alholva (Spain), etc.
  • the seeds of the plant are used worldwide as spices for condiments and in recipes for soups and pancakes, while the leaves are used as green leaf vegetables in food.
  • the seeds have a bitter flavour and have been used for 2500 years for their medicinal properties, primarily as a remedy for anorexia and as a gastric stimulant.
  • the seeds are considered to have a carminative and antibacterial effect thanks to the components of which they are constituted.
  • the principal component is fibres (50%), both insoluble (20%) and soluble (30%) in the form of galactomannan.
  • the seeds also contain lipids (7.5%) in the form of triglycerides and phospholipids, steroidal saponins (4-8%) and alkaloids (1%) which contribute to their bitter flavour and stimulate the appetite.
  • the remaining part of the seed is composed primarily of proteins (30%) and small amounts of vitamins and minerals.
  • the high concentration of fibre in fenugreek seeds make them one of the major natural sources of fibre; and, specifically, 30% of the fibres is soluble and able to form a gel like guar gum, oat bran and psyllium mucilage.
  • fenugreek fibres Another important characteristic of fenugreek fibres is their high stability, which gives them a long product shelf-life since they are not degraded by cooling or after cooking.
  • the most common indication for the use of fenugreek seeds is associated with the capacity of the fibres to increase intestinal regularity, reduce the risk of constipation without stimulating flatulence, and reduce the risk of diverticulitis and hemorrhoids.
  • the fibres are able to induce a sense of satiety and can contribute to weight loss without compromising an appropriate intake of protein.
  • Another property which has been documented in numerous studies is their capacity to reduce plasmatic glycemia and glycosuria.
  • the literature includes numerous studies on the hypoglycemic action of fenugreek seeds in mice, rats and diabetic rats and dogs, as well as human subjects.
  • fenugreek seeds, and the fibre they contain may be effective in treating gastric acidity and gastroesophageal reflux.
  • composition according to the present invention comprises an extract of Trigonella foenum graecum, preferably a dry extract, and more preferably a dry extract of the seeds of Trigonella foenum graecum obtained by means of standard extraction methods known to the person skilled in the art, in particular water or hydroalcoholic extraction methods.
  • the extract of Trigonella foenum graecum is present in an amount comprised between 10% and 95% by weight relative to the total weight of the composition, more preferably the extract of Trigonella foenum graecum is present in a concentration by weight comprised in a range of 15 to 90%, or 25% to 85%, or 30% to 80% relative to the total weight of the composition.
  • the Applicant has found that the action of fenugreek in vivo is further increased by its synergistic action with the poloxamer polymer. Said synergy does not benefit from the use of methylcellulose and derivatives thereof.
  • polystyrene resin a series of copolymers of ethylene oxide and propylene oxide (CAS number: 9003-11-6 or 106392-12-5). These are three block copolymers with the following structural formula:
  • poloxamers have similar molecular structures, also indicated as PEG-PPG-PEG, with different molecular weights and compositions of the blocks of polyoxyethylene (x) and polyoxypropylene (y).
  • x polyoxyethylene
  • y polyoxypropylene
  • molecular weight ranging from 9840 to 14600 Da.
  • polymers are widely used in pharmaceutical formulations as surfactants, emulsifiers, solubilizers, dispersing agents and enhancers of in vivo absorption (examples of tradenames: Pluronic ® , Synperonic ® , Kolliphor ® ).
  • Poloxamers are considered to be "functional excipients", since they are essential components and play an important role in such formulations.
  • the gelification mechanism is based on the solubility of the polyoxypropylene block.
  • Increasing the temperature above the micellisation temperature (which corresponds to a drastic reduction in the solubility of the polyoxypropylene block) leads to an aggregation of the central polyoxypropylene section of the polymer and the consequent formation of micelles, composed of a polyoxypropylene core and lateral polyoxyethylene chains. Further increasing the temperature leads to the gelification of the micelles. This derives from the stacking of the micellar structures.
  • Poloxamer 407 forms aqueous solutions with a sol-gel transition temperature at around 25°C, while solutions of poloxamer 188 have a sol-gel transition temperature above 40°C.
  • Aqueous solutions of mixtures of the two polymers gelify at intermediate temperatures.
  • the aqueous solution of a mixture of poloxamer 407 and poloxamer 188 with a ratio by weight of 2: 1 is the most advantageous, since it has a sol-gel transition temperature around 37°C, i.e. human body temperature.
  • the poloxamers have muco-adhesive properties which are very significant in technological terms for the creation of prolonged release pharmaceutical forms.
  • the inventors have found that, due to its muco- adhesive properties, the mixture of one or more poloxamers adheres to the esophageal and gastric mucus membranes, preventing contact with the material deriving from gastroesophageal reflux and hence preventing damage to the mucus membranes themselves.
  • the combined action of the extract of Tngonella foenum graecum and the poloxamer, preferably a mixture of poloxamers, is particularly advantageous for the therapeutic or preventive treatment of the symptoms of GERD and its associated pathologies and disorders.
  • the poloxamer is present in an amount comprised between 1% and 80% by weight relative to the total weight of the composition, more preferably the poloxamer is present in a concentration by weight of 1.5 to 70%, or 2.5% to 60%, or 5 to 50% relative to the total weight of the composition.
  • the present composition may be used for the treatment of gastric and esophageal pathologies, in particularly of gastroesophageal reflux disease.
  • the effectiveness of the composition is derived from the following activity of its components:
  • the extract of a plant of the genus Tngonella (Tngonella foenum graecum), containing glucomannan in particular, gelifies in contact with the gastric fluids and forms a protective barrier which prevents the reflux of acid towards the esophagus.
  • the poloxamer has the capacity to bind with the mucus membranes of the esophagus and the stomach.
  • the interaction of this polymer with the esophageal mucus membrane prevents contact with the reflux acid, thus protecting the mucus membrane against damage by the acid itself.
  • the synergistic action occurs between the extract of a plant belonging to the genus Trigonella and at least one poloxamer, preferably poloxamer 188 or poloxamer 407 or a mixture thereof.
  • the synergy is enhanced when the extract of the plant of the genus Trigonella (Trigonella foenum graecum) is present to an amount comprised from 10 mg to 10000 mg and at least one poloxamer is present in an amount comprised from 10 mg to 10000 mg, preferably in a ratio of poloxamer 407 to poloxamer 188 respectively of 4:1 to 0.5:1 , preferably 2:1 to 1 : 1.
  • Trigonella Trigonella foenum graecum
  • said extract of Trigonella foenum graecum (a) is in the form of a dry extract, preferably with a total fibre title of 50% to 95%, more preferably 60 to 90% or 75 to 85%, of the total weight of the extract.
  • the block copolymer (b) is a poloxamer.
  • the block copolymer (b) is poloxamer 407, poloxamer 188, or a mixture thereof.
  • the block copolymer (b) is a mixture of poloxamer 407 and poloxamer 188, more preferably with a ratio by weight of 4: 1 to 0.5:1 , even more preferably with a ratio by weight of 2: 1 to 1 : 1.
  • the composition according to the present invention may be for use in human subjects or for veterinary use, for example, but without limitation, in pets like cats and dogs or in other mammals.
  • the composition according to the present invention is for use in human subjects.
  • the composition is administered to the subject orally, for example in the form of tablets, pills, whether coated or not, capsules, solutions, suspensions, syrups, food containing the active ingredients or any other form known to a person skilled in the art.
  • the administration of (a) and (b) may be simultaneous, for example in a single formulation, or in rapid succession, for instance by means of two or more formulations ingested by the subject in any order, in close succession (e.g. within 1 to 10 minutes) in two distinct compositions.
  • composition or composition for use according to the present invention may comprise, in addition to (a) and (b), at least one inert ingredient, such as at least one excipient among those in common use and known to the person skilled in the art.
  • inert ingredient any substance, or combination of substances, auxiliary to the production of a pharmaceutical, food or nutraceutical form, to be found in the finished product and which is not the active ingredient, although it may modify its stability, release or other characteristics.
  • Non-limiting examples of such ingredients are excipients such as diluents, absorbents, adsorbents, lubricants, glidants, colourants, surfactants, antioxidants, sweeteners, flavourings, binders, disintegrating agents, plasticisers, thickeners, emulsifiers, humectants, wetting agents, preservatives, chelating agents and the like.
  • excipients such as diluents, absorbents, adsorbents, lubricants, glidants, colourants, surfactants, antioxidants, sweeteners, flavourings, binders, disintegrating agents, plasticisers, thickeners, emulsifiers, humectants, wetting agents, preservatives, chelating agents and the like.
  • the composition or composition for use according to the present invention comprises, in addition to (a) and (b), at least an additional natural or synthetic active ingredient.
  • active ingredients are antacids, alginates and other muco-adhesive polymers, prokinetics and active ingredients capable of inhibiting the secretion of hydrochloric acid by the gastric parietal cells.
  • the term "medical device” is used in its meaning pursuant to Italian Legislative Decree 24 February 1997, n. 46, and Directive 93/42/EEC 14 June 1993, i.e. it indicates a substance or other product, used alone or in combination, intended by the manufacturer to be used in human subjects for the diagnosis, prevention, control, therapy or attenuation of a disease, said product not exercising the principle action, in or on the human body, for which it is intended, with pharmacological or immunological means nor via metabolic processes, but the function of which may be assisted by said means.
  • composition for example a suspension or gel
  • pharmaceutical or nutraceutical compositions by non-limiting example, in the form of capsules, tablets, at least partially hydrosoluble or orosoluble powders, granules, pellets, microparticles, optionally contained in a sachet or capsule or tablet (mini- tablet), liquid or semisolid preparation, gel, suspension, solution, two-phase liquid system and equivalent forms.
  • the present invention further provides a method of treatment, therapeutic or preventive, for gastroesophageal reflux disorders or disease and its associated pathologies and disorders in a subject in need thereof, wherein said method of treatment provides for the administration to said subject of an effective amount of the composition according of the invention in any of the embodiments described above, preferably said administration is oral and the composition of the present invention is in one of the above forms of administration.
  • the present invention relates also to the non-therapeutic use of the composition of the invention according to any of the embodiments described above for the non-therapeutic treatment of gastroesophageal reflux disorders and its associated disorders in a subject in need of said non-therapeutic treatment.
  • Trigonella foenum graecum e.s. 400 mg
  • composition according to the present invention for the treatment of gastroesophageal reflux.
  • mice of the ICR strain supplied by the company Charles River and weighing 20-25 g were used.
  • the animals were housed in temperature-controlled rooms (temperature of 23 + 2°C, humidity 50 + 2%, 12- hour light-dark cycles).
  • the mice had free access to water and food, which consisted of a standard diet supplied by the company Mucedola Mangimi (Settimo Milanese, Italy). All experiments were performed in observance of Legislative Decree no. 116 of 27 January 1992 and according to the guidelines of the Council of the European Union (86/609/EEC and 2010/63/EU).
  • Gastric emptying was evaluated with the method described by Smits and Lefebvre (Exp. Gerentol. 1996, 31 (5):589-96).
  • a marker 0.2 ml/mouse of a suspension containing 50 mg of phenol red in 100 ml of 1.5% carboxymethylcellulose.
  • the animals were sacrificed in a CO2 saturated atmosphere and the stomach was removed.
  • the stomach was subsequently positioned inside a test tube containing 4 ml of saline solution; after 20 seconds of shaking, 2 ml of NaOH 1 M was added to each test tube in order to achieve the maximum colour intensity.
  • Spectrophotometric analysis (560 nm) was carried out on 1 ml of this solution.
  • the percentage of gastric emptying was calculated according to the following formula: 100 X (1 - [amount of phenol red present in the stomach after 20 min) / (amount of phenol red present in the stomach at time 0]).
  • mice Four hours after the surgical procedure (time necessary to determine a submaximal lesion of the mucosa of the esophagus), the mice were sacrificed in a CO2 saturated atmosphere and the esophagus and stomach were removed for evaluation of: 1) the macroscopic esophageal and gastric damage, 2) the degree of esophageal and gastric inflammation (activity of myeloperoxidase) and 3) the characteristic parameters of gastric secretion (volume of the gastric contents, pH and total acidity).
  • MPO myeloperoxidase
  • the supernatants were incubated with NaPP (sodium phosphate buffer pH 5.5) and TMB 16 mM (tetramethylbenzidine) and, after five minutes of incubation at room temperature, H2O2 diluted in NaPP was added.
  • the reaction was blocked with cold acetic acid 2M and a reading of 1 ml of the reaction solution was taken on a spectrophotometer at a wavelength (X) of 650-655 nm. The values obtained were compared to a standard MPO curve and the results expressed as U/ml of MPO.
  • the combination of the poloxamers with the fibres was prepared using the cold method. Distilled water was added to a certain amount of poloxamer and vegetable fibre at a temperature of 4°C. The mixture was lightly stirred for approximately 18 hours to dissolve the polymers.
  • a vial containing a magnetic stirring bar and the mixture of poloxamer and fibre was placed inside a thermostatically controlled bath.
  • a thermistor or thermocouple temperature sensor was placed inside the vial.
  • the vial was heated at a rate of 1 0 C/min under continuous stirring at 30 rpm.
  • the sol/gel transition temperature is that recorded by the temperature sensor when the rotation of the magnetic bar was stopped by the gelification of the mixture of poloxamer and fibre.
  • the simulated gastric fluid (SGF) was prepared to measure the muco-adhesion in accordance with the Italian Pharmacopoeia. 2.0 g of sodium chloride and 3.2 g of pepsin in powder form were dissolved in ultrapure water. To this was added 80 ml_ of HC1 1 M, and the solution brought to a final volume of 1000.0 ml with ultrapure water.
  • the rheological analysis was conducted using a rotational rheometer equipped with a cone/plate combination as the measurement system. All samples were subjected to measurement of their viscosity at 25°C and 37°C using an increasing shear speed in the range 10-300 s 1 .
  • thermoregulation time of 900 s was employed.
  • the muco-adhesive properties of the samples diluted with SGF were studied using the inclined plane test.
  • the equipment consisted of an inclined plane (angle of inclination: 60 °, surface: 28 cm 2 ) temperature controlled at 37°C, and electronic micro-scales connected to a PC.
  • Pig gastric mucin was used as the biological substrate.
  • the films of mucin were prepared directly on the plane: 2.5 ml of mucin dispersion at 8% p/p in a pH 4.5 acetate buffer was placed on the plane, which was held horizontal at 45°C for 45 minutes.
  • the samples were placed on the plane previously coated with the biological substrate and held horizontal. The plane was then inclined and the amount of sample which fell onto the micro-scales recorded as a function of time.
  • the in vitro float time was determined by analysing the floating lag time and the variable duration for all compositions.
  • the test was conducted by placing 5 mL of the raft systems (placed on the clock glass) in a 125 mL beaker containing 100 mL of HCI 0.1 N (pH 1.2) and the system was held at 37°C ⁇ 0.5°C in a water bath. Their physical state was monitored for 20 hours. The following were measured: the time between the introduction of the dosage form (e.g. the composition according to the invention or its individual components) and its hydrostatic thrust on the HCI 0.1 N (FLt) and the time during which the dosage form remained floating (float time). Three repeat measurements were made for each composition.
  • the dosage form e.g. the composition according to the invention or its individual components
  • FLt hydrostatic thrust on the HCI 0.1 N
  • the swelling index is the volume in mL occupied by 1 g of test material (e.g. the composition according to the present invention or its individual components) after swelling in an aqueous solution for 4 hours.
  • the swelling index was compared using the method indicated in the European Pharmacopoeia 6.0.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition destinée à être utilisée dans une méthode de traitement de troubles ou de la maladie du reflux gastro-oesophagien, de préférence dans une méthode pour le traitement symptomatique de troubles ou de la maladie du reflux gastro-oesophagien, ladite composition étant destinée à une utilisation orale, sous une forme quelconque d'administration pharmaceutiquement acceptable, et comprend un mélange comprenant ou, en variante, constitué d'un extrait de Trigonella foenum graecum et d'un copolymère séquencé d'oxyde d'éthylène et d'oxyde de propylène.
PCT/IB2018/055854 2017-08-08 2018-08-03 Composition pour administration orale dans le traitement thérapeutique ou préventif de troubles ou de la maladie du reflux gastro-oesophagien WO2019030629A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18762148.7A EP3664852A1 (fr) 2017-08-08 2018-08-03 Composition pour administration orale dans le traitement thérapeutique ou préventif de troubles ou de la maladie du reflux gastro-oesophagien

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102017000091733A IT201700091733A1 (it) 2017-08-08 2017-08-08 Composizione per somministrazione orale per uso nel trattamento terapeutico o preventivo dei disturbi o malattia da reflusso gastroesofageo
IT102017000091733 2017-08-08

Publications (1)

Publication Number Publication Date
WO2019030629A1 true WO2019030629A1 (fr) 2019-02-14

Family

ID=60991127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/055854 WO2019030629A1 (fr) 2017-08-08 2018-08-03 Composition pour administration orale dans le traitement thérapeutique ou préventif de troubles ou de la maladie du reflux gastro-oesophagien

Country Status (3)

Country Link
EP (1) EP3664852A1 (fr)
IT (1) IT201700091733A1 (fr)
WO (1) WO2019030629A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050005A1 (fr) * 1999-02-24 2000-08-31 Dong Wha Pharm. Ind. Co., Ltd Composition de suppositoire liquide au diclofenac sodique
WO2007133082A1 (fr) * 2006-05-16 2007-11-22 Frutarom Netherlands B.V. Procédé de réduction des symptômes de pyrosis et de reflux gastro-œsophagien (rgo) par des polysaccharides spécifiques
US20110229569A1 (en) * 2008-09-22 2011-09-22 Rubicon Research Private Limited Compositions exhibiting delayed transit through the gastrointestinal tract
PL218041B1 (pl) * 2006-06-28 2014-09-30 Akademia Medyczna Im Piastów Śląskich We Wrocławiu Zastosowanie Poloksameru 407 wraz z metylocelulozą do wytwarzania płynnego leku do osłony i leczenia błony śluzowej oraz sposób jego wytwarzania

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050005A1 (fr) * 1999-02-24 2000-08-31 Dong Wha Pharm. Ind. Co., Ltd Composition de suppositoire liquide au diclofenac sodique
WO2007133082A1 (fr) * 2006-05-16 2007-11-22 Frutarom Netherlands B.V. Procédé de réduction des symptômes de pyrosis et de reflux gastro-œsophagien (rgo) par des polysaccharides spécifiques
PL218041B1 (pl) * 2006-06-28 2014-09-30 Akademia Medyczna Im Piastów Śląskich We Wrocławiu Zastosowanie Poloksameru 407 wraz z metylocelulozą do wytwarzania płynnego leku do osłony i leczenia błony śluzowej oraz sposób jego wytwarzania
US20110229569A1 (en) * 2008-09-22 2011-09-22 Rubicon Research Private Limited Compositions exhibiting delayed transit through the gastrointestinal tract

Also Published As

Publication number Publication date
EP3664852A1 (fr) 2020-06-17
IT201700091733A1 (it) 2019-02-08

Similar Documents

Publication Publication Date Title
US9610315B2 (en) Compositions for the treatment of gastro-esophageal reflux disease (GERD)
RU2432167C2 (ru) Способ уменьшения симптомов изжоги и гастроэзофагиальной рефлюксной болезни (гэрб) с помощью особых полисахаридов
JP2018203787A (ja) 胆汁酸捕捉剤の胃内滞留型徐放性経口剤形
ES2719898T3 (es) Composiciones orales para el tratamiento de la enfermedad de reflujo gastroesofágico
EP3124048B1 (fr) Composée orale destinée au traitement des maladies ou affections gastro-oesophagiennes
TW200930385A (en) Composition with active ingredient combination for the treatment of constipation
JP4405399B2 (ja) 抗潰瘍薬草配合物
CN106390065A (zh) 半夏厚朴中药制剂在治疗和/或预防反流性咽喉炎中的用途
EP3664852A1 (fr) Composition pour administration orale dans le traitement thérapeutique ou préventif de troubles ou de la maladie du reflux gastro-oesophagien
CN100431578C (zh) 一种治疗前列腺增生的中药制剂
US11723939B2 (en) Composition for gastric and oesophageal diseases
JPH09505824A (ja) 便秘の治療におけるジメチコーンの使用
WO2023026231A1 (fr) Composition pour la prévention et/ou le traitement de maladies gastriques et oesophagiennes
Rex Gastroesophageal reflux disease in adults: pathophysiology, diagnosis, and management
EP4240372A1 (fr) Composition destinée à être utilisée dans la prévention et le traitement de maladies du système gastro-intestinal et des symptômes associés
WO2023026227A1 (fr) Composition pour la prévention et/ou le traitement de maladies gastriques et oesophagiennes
EP4059506A1 (fr) Composition pour le traitement de l' sophagite par reflux et des symptômes associés
TWI477280B (zh) 治療、改善女性生理期與經期症候群的巧克力草本中藥複方組合物
EA041032B1 (ru) Пероральная композиция для лечения гастроэзофагеального рефлюкса
Kuraganti Evaluation of Anti-Ulcer Activity of Aqueous and Alcoholic Extracts of Nelumbo Nucifera in Rats

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18762148

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018762148

Country of ref document: EP

Effective date: 20200309